Lataa...
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal an...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6249335/ https://ncbi.nlm.nih.gov/pubmed/30498492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02616 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|